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Abstract
Background: Tissue Factor (TF) forms a proteolytically active complex together with coagulation factor VIIa (FVIIa)
and functions as the trigger of blood coagulation or alternatively activates cell signaling. We recently described that
EphA2 of the Eph tyrosine kinase receptor family is cleaved directly by the TF/FVIIa complex. The aim of the present
study was to further characterize the cross-talk between TF/FVIIa and EphA2 using in vitro model systems and
human cancer specimens.
Methods: Cleavage and phosphorylation of EphA2 was studied by Western blot. Subcellular localization of TF and
EphA2 was investigated by a proximity ligation assay and confocal microscopy. Phalloidin staining of the actin
cytoskeleton was used to study cell rounding and retraction fiber formation. Expression of TF and EphA2 in human
colorectal cancer specimens was examined by immunohistochemistry.
Results: TF and EphA2 co-localized constitutively in MDA-MB-231 cells, and addition of FVIIa resulted in cleavage of
EphA2 by a PAR2-independent mechanism. Overexpression of TF in U251 glioblastoma cells lead to co-localization
with EphA2 at the leading edge and FVIIa-dependent cleavage of EphA2. FVIIa potentiated ephrin-A1-induced cell
rounding and retraction fiber formation in MDA-MB-231 cells through a RhoA/ROCK-dependent pathway that did
not require PAR2-activation. TF and EphA2 were expressed in colorectal cancer specimens, and were significantly
correlated.
Conclusions: These results suggest that TF/FVIIa-EphA2 cross-talk might potentiate ligand-dependent EphA2
signaling in human cancers, and provide initial evidence that it is possible for this interaction to occur in vivo.
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Background
The Eph receptors are the largest family of receptor tyro-
sine kinases (RTKs) in humans with 14 members. Eph
receptors are activated by cell–bound ephrin ligands, and
the Eph-ephrin system governs contact-dependent inter-
cellular communication controlling a wide array of
biological processes such as development, tissue orga-
nization and cell migration [1, 2]. EphA2 of the A type
Eph subclass is expressed at low levels in differentiated
tissues but expression frequently increases in advanced
cancers, implicating EphA2 in tumor progression [3]. The
preferred ligand for EphA2 is ephrin-A1 [4], and ligation
of EphA2 by ephrin-A1 leads to the formation of multi-
meric receptor-ligand clusters that activate a signaling
response that controls cytoskeletal dynamics and cell
morphology. While ligand-dependent EphA2-activation
has been considered tumor suppressive, recent reports
have highlighted a role for EphA2-ephrin-A1 signaling in
tumor cell plasticity and a shift from mesenchymal to
amoeboid morphology [5, 6] and increased single cell
invasion [7]. In addition, oncogenic EphA2 signaling has
been proposed to be ligand-independent, drawing from
the observations of decreased expression of the ephrin-
A1 ligand paralleling increased EphA2 expression in
human cancers [8]. Miao et al. showed that EphA2 is a
substrate and effector of PI3 kinase/Akt signaling through
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phosphorylation of serine 897 in the EphA2 cytoplasmic
domain, a pathway by which EphA2 controls cancer cell
motility and invasion independently of ephrin-A1 [9, 10].
Tissue Factor (TF) is the receptor and co-factor for co-
agulation factor VII/VIIa (FVII/FVIIa), a circulating serine
protease. The proteolytic TF/FVIIa complex functions as
the physiological trigger of blood coagulation and in
addition activates cell signaling through mechanisms
dependent or independent of protease-activated receptors
(PARs) and the TF cytoplasmic domain [11]. TF expres-
sion is found in tumor cells [12], and in preclinical
models, TF/FVIIa signaling has been implicated in tumor
progression through effects on processes such as cell mi-
gration and angiogenesis [13, 14]. Furthermore, a clinically
relevant role of the coagulation system in malignancies is
evidenced by the increased risk of thrombosis in cancer
patients. In contrast, anticoagulant treatment only mod-
estly influences cancer incidence and survival in humans,
and the effect seem to differ between cancer types [15].
We previously reported on a direct cleavage by TF/FVIIa
in the ligand binding domains (LBD) of the Eph receptors
EphB2 and EphA2. We also identified a conserved disulfide
bond that kept the N-terminal fragment tethered to the re-
ceptors after cleavage [16]. In this study we set out to fur-
ther explore how TF/FVIIa influences EphA2 signaling and
activity. We report herein that TF and EphA2 co-localizes
in MDA-MB-231 breast cancer cells with constitutive high
TF expression and in TF transfected U251 glioblastoma
cells, and that FVIIa sensitizes MDA-MB-231 cells to
ephrin-A1-mediated cytoskeletal reorganization and cell
rounding independently of PAR2-activation through a
RhoA/ROCK pathway. EphA2 and TF were co-expressed
in a cohort of human colorectal cancer specimens, provid-
ing evidence that the prerequisites for TF–EphA2 cross-
talk in vivo are present.
Methods
Reagents
Antibodies towards EphA2 (6997), pS897-EphA2 (6347),
pY588-EphA2 (12677) and GAPDH (2118) were from
Cell Signaling Technology. The RhoA antibody (ARH04)
was from Cytoskeleton. The TF antibody (clone 10H10)
was a kind gift from Professor J Morrissey (University of
Illinois) and the PAR2 blocking antibody was a kind gift
from Professor W Ruf (Scripps Institute). PI3 kinase
inhibitor LY294002 was from Calbiochem and ROCK in-
hibitor Y-27632 from Sigma.
Cell culture
MDA-MB-231 cells were obtained from the American
Type Culture Collection and cultured in complete RPMI
1640 medium. For experiments, cells were seeded in in-
dividual wells and left to attach over night. Cells were
then switched to medium containing 0.1 % FBS, for the
FVIIa groups supplemented with 10 nM FVIIa for 1 h
and then stimulated with ephrin-A1 or Fc control as in-
dicated in the figure legends. Prior to experiments,
ephrin-A1 was preclustered for 1 h at room temperature
with anti-human Fc goat IgG (Jackson ImmunoRe-
search) at 1:10 concentration. Preclustered Fc fragments
(Jackson Immunoresearch) were used as controls. In
some cases, cells were pretreated for 30 min with inhibi-
tors prior to stimulations.
U251 cells were from Cell Line Services and were cul-
tured in complete DMEM medium. Experiments were
performed in DMEM with 0.1 % FBS.
SDS-PAGE and Western blot
SDS-PAGE and Western blot was performed using the
Novex Bis-Tris gel system (Life Technologies) as previ-
ously described [14].
mRNA analyses
Total RNA was extracted from cells by Trizol® (Life Tech-
nologies) using standard protocols, and converted to cDNA
using oligoDT primers. Quantitative real-time PCR (qPCR)
was performed using Assays on demand (Applied Biosys-
tems) for IL8 with β2-microglobulin as housekeeping gene
on an ABI prism 7500 system. Results were calculated
using the comparative CT method for separate tubes.
siRNA knock-down of RhoA
MDA-MB-231 cells were transfected with 10 nM RhoA
siRNA (Silencer select, Ambion) using Lipofectamine
RNAiMAX (Life Technologies) according to instructions
from the manufacturer. Cells were assayed 48 h after
transfection. Efficiency of protein knock-down was ana-
lyzed by Western blot.
In situ proximity ligation assay
The assay was performed with reagents supplied by the
manufacturer (Olink Bioscience) and according to instruc-
tions supplied with the kit. In brief, MDA-MB-231 cells
were grown on chamber slides (Lab Tek), fixed in 4 %
PFA/PBS, blocked and incubated with antibodies towards
TF and EphA2, which were bound by secondary anti-
bodies connected to specific oligonucelotides that ligate
when they are in close proximity. Ligated oligonucleotides
then serve as template for a rolling-circle amplification
and the amplification products were visualized by fluores-
cently labeled probes. Cell nuclei were stained with DAPI
and images captured with a 40x objective using a Zeiss
Axioimager fluorescence microscope.
Confocal microscopy
For microscopy experiments, cells were grown on 8-well
chamber slides (Lab Tek), and then washed with PBS and
fixed in 4 % PFA. Cells were permeabilized with 0.2 %
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Triton X-100 and subsequently blocked in 2 % BSA for
30 min. Antibody incubations were performed for 1 h at
room temperature for primary antibodies (EphA2 1:200, TF
1:500) and 30 min in the dark at room temperature for sec-
ondary antibodies (1:1000) (Molecular Probes). Staining of
the actin cytoskeleton with phalloidin-FITC (Sigma) diluted
1:500 was performed together with the secondary anti-
bodies. Slides were washed with PBS between all steps, and
mounted in Vectashield mounting medium with DAPI and
sealed with nail varnish. Confocal images were captured
with a Zeiss LSM710 confocal microscope using the 40x or
63x objectives.
Assay for cell rounding and retraction fiber formation
MDA-MB-231 cells were seeded on 8-well chamber slides
(Lab-Tek) coated with 10 μg/ml collagen IV (Sigma) and
left to attach over night. After treatments, cells were
washed with PBS and fixed in 4 % PFA/PBS. The cytoskel-
eton was stained by FITC-conjugated phalloidin (Sigma)
for 30 min at room temperature protected from light. Slides
were then washed, mounted in mounting media with DAPI
and sealed with nail varnish. Images were captured using
an Axiovert 40 CFL inverted epifluorescence microscope
(Zeiss) and the 40x objective. 3–4 images per well were
taken at random locations and the percentage of cells with
rounded morphology and retraction fibers was quantified
according to Taddei et al. [17].
TF overexpression
U251 cells were transfected to transiently overexpress TF
by using Lipofectamine 3000 (Life Technologies) and a
plasmid encoding untagged human TF (Origene). Briefly,
cells were seeded in 24-well plates, left to attach over night
and transfected with 400 ng DNA. Lipofectamine without
DNA was used as control, and stimulations were performed
24 h post transfection in low serum DMEM.
Immunohistochemistry (IHC) of colorectal cancer
specimens
The patient cohort used in the study contained non-
consecutive cases diagnosed with colorectal cancer be-
tween 1990 and 2003 in the Uppsala region in Sweden,
collected with the purpose to screen for protein expres-
sion differences between disease stages and between
normal colorectal tissue, cancer and metastases. The co-
hort included 60 patients, with 20 (33 %) patients each
in stages I, II and III. 41 (68 %) cases were colon cancers
and 19 (32 %) cases were rectal cancers. 10 cases each of
colorectal normal tissues and adenomas as well as 20
cases of lymph node or distant metastases were also in-
cluded. Tumor and patient characteristics were based on
the original histopathology reports and the patients’
clinical records.
All tumor material was present as formalin-fixed
paraffin-embedded tissue in duplicate cores on tissue mi-
croarrays (TMAs), constructed at the SciLife Laboratory
Tissue Profiling Facility at Uppsala University as described
previously [18]. Expression of TF and EphA2 was detected
by IHC using a rabbit polyclonal TF antibody developed by
the Human Protein Atlas project [19] and a rabbit mono-
clonal EphA2 antibody (6997, Cell Signaling Technology).
Automated IHC staining were performed as previously
described [20], using a LabVision Autostainer 480S (Ther-
moFisher Scientific). Microarray sections were baked over
night, deparaffinized, hydrated in graded alcohols and
blocked for endogenous peroxidase using 0.3 % hydrogen
peroxide. Following antigen retrieval, sections were stained
with primary antibody (30 min) and secondary dextran
polymer visualization system (30 min), followed by the
addition of diaminobenzidine as chromogen. All solutions
except primary antibodies were obtained from Laboratory
Vision (Laboratory Vision). Sections were counterstained in
Mayer’s hematoxylin (Histolab), before dehydration and
mounting of coverslip. Stained slides were digitalized by
scanning, using an Aperio ScanScope XT Slide Scanner
(Aperio Technologies). Tumor cell staining was anno-
tated semi-quantitatively with respect to staining in-
tensity and fraction of positive cells. Intensity was
graded as negative, weak, moderate or strong, and
graded in six fractions (0–1 %; 2–10 %; 11–25 %; 26–
50 %, 51–75 %; >75 %) and specimens with moderate
or strong staining in more than 2 % of tumor cells were
considered positive.
During TMA sectioning 6 primary cancer cases and 3
metastases were lost or compromised, resulting in TMA
cores with no representative tumor tissue present. These
cases were not annotated and excluded from all statis-
tical analyses.
Statistics
Statistics were performed using the GraphPad Prism
(GraphPad Software) and Statistica (Statsoft Scandi-
navia) softwares. Unpaired two-tailed t-test was used to
compare experimental groups. For comparison of TF
and EphA2 expression in colorectal cancer non-
parametric correlation was calculated according to
Spearman, and Chi-squared tests were used to compare
groups defined by TF and/or EphA2. P-values equal to
or below 0.05 were considered statistically significant.
Results
Subcellular localization of TF and EphA2
We recently identified EphB2 and EphA2 as novel
proteolytical substrates of TF/FVIIa, and located the
cleavage site to a conserved arginine residue in the
ligand-binding domain [16]. Here we set out to fur-
ther analyze the EphA2 cleavage mechanism. As seen
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in Fig. 1, EphA2 is cleaved upon stimulation of
MDA-MB-231 breast cancer cells with FVIIa, with
the truncated EphA2 isoform appearing as band mi-
grating around 95 kDa on SDS-PAGE. In line with a
direct cleavage mechanism, we previously showed that
EphB2 was cleaved independently of proteolytic acti-
vation of the prototypic TF/FVIIa signaling receptor
PAR2. Here we confirmed the PAR2-independence for
EphA2 cleavage, as formation of the truncated EphA2 spe-
cies by TF/FVIIa was not prevented by a PAR2-blocking
antibody or the 10H10 anti-TF antibody specifically pre-
venting PAR2-activation [21] (Fig. 1a), demonstrating a
similar mechanism as for EphB2. The PAR2-blocking anti-
body was verified in our lab previously [22] and we also
found that the 10H10 antibody prevented TF/FVIIa-PAR2
induced IL8 mRNA transcription as has been reported by
others [21] (Fig. 1a).
These results supported a direct cleavage mecha-
nism, which would require a co-localization between
the protease and the substrate. Using the in situ
proximity ligation method [23] to detect protein
interactions we found that TF and EphA2 constitu-
tively co-localized in MDA-MB-231 cells as measured
by an abundance of signals corresponding to TF and
Fig. 1 Co-localization between TF and EphA2 in MDA-MB-231 cells. a EphA2 cleavage is independent of PAR2. MDA-MB-231 cells were pretreated with
50 μg/ml anti-TF antibody 10H10 or 100 μg/ml PAR2-blocking antibody for 30 min followed by 10 nM FVIIa for 6 h. Images show representative Western
blots. The 10H10 antibody was verified to prevent IL8 mRNA induction by FVIIa (graph). MDA-MB-231 cells were pre-treated with 50 μg/ml 10H10 antibody
for 30 min, and 10 nM FVIIa was added for 1 h. FVIIa increased IL8 mRNA to 224.6 ± 0.3 %, whereas preincubation with mab10H10 abolished induction to
112.6 ± 1.2 %. N= 2, results are presented as percent of untreated control with error bars indicating the standard deviation. b EphA2 and TF in proximity
were detected in MDA-MB-231 cells using an in situ proximity ligation assay with antibodies towards TF and EphA2. Red signal corresponds to TF-EphA2
complexes, blue signal represents DAPI-stained DNA. c Confocal micrographs showing MDA-MB-231 cells stained for EphA2 (green signal) and TF (red
signal). Blue signal represents DAPI-stained DNA. Scale bar represents 20 μm
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EphA2 in close proximity (Fig. 1b). We also immuno-
stained MDA-MB-231 cells for TF and EphA2 and
generated micrographs by confocal microscopy. TF
and EphA2 both localized to cell membranes and co-
localization was especially evident at cell-cell contacts
(Fig. 1c), supporting an association between TF/FVIIa
and EphA2. Secondary antibody controls showed no
evidence for unspecific staining (Additional file 1). We
compared these results to the U251 glioblastoma cell
line, which expresses high levels of EphA2 but low
amounts of TF, and confocal microscopy analysis
showed a strong membranous EphA2 staining but a
weak TF signal (Fig. 2a). Furthermore, EphA2 cleavage
by FVIIa was not detected in these cells even after
prolonged stimulations (Fig. 2c). We reasoned that a
higher expression of TF than what was present in
Fig. 2 Overexpression of TF is required for EphA2 co-localization and cleavage in U251 cells. a-b U251 cells were transfected with a plasmid encoding
human TF or treated with Lipofectamine alone as control. The figure shows confocal micrographs of control (a) or TF transfected (b) U251 cells
stained for EphA2 (green signal) and TF (red signal). Blue signal represents DAPI-stained DNA. Scale bar represents 20 μm. c Lipofectamine-treated or
TF-transfected U251 cells were treated with 10 nM FVIIa for the indicated time points. Samples were analyzed for EphA2 and TF expression by Western
blot. N = 2–3, representative blots are shown
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wild-type cells was necessary to allow sufficient
complex formation with EphA2 at the cell surface, and
in order to test this hypothesis we increased TF ex-
pression in these cells by transient overexpression. In
contrast to wild type cells, TF appeared in transfected
cells as an intense membranous staining with strong
clustering at the leading edge and evident co-
localization with EphA2 (Fig. 2b). In TF-transfected,
but not wild-type cells, stimulation with 10 nM FVIIa
resulted in robust EphA2 cleavage indicating that high
levels of TF expression resulting in co-localization
with EphA2 is necessary for FVIIa to be able to cleave
EphA2 (Fig. 2c).
FVIIa potentiates ephrin-A1 induced cell rounding
independently of PAR2-cleavage
Given the interaction between TF and EphA2 we next
set out to investigate how formation of the TF/FVIIa
complex would affect EphA2 signaling and its acti-
vation by the ligand ephrin-A1. Ligand-dependent
forward signaling by EphA2 frequently targets the cyto-
skeleton, with EphA2 activation by ephrin-A1 leading
to cytoskeletal rearrangements and cell rounding [17].
We stained MDA-MB-231 cells with phalloidin to
visualize the actin cytoskeleton and found that EphA2
was enriched at clusters of dynamic actin fibers and at
cell-cell contacts (Fig. 3a).
Fig. 3 EphA2 co-localize with f-actin and FVIIa stimulation potentiates ephrin-A1-induced cell rounding and retraction fiber formation in MDA-
MB-231 cells. a EphA2 co-localizes with the actin cytoskeleton in MDA-MB-231 cells. Confocal micrographs showing EphA2 (red signal) and actin
fibers stained by phalloidin (green signal). Blue signal represents DAPI-stained DNA. b MDA-MB-231 cells were plated on collagen IV and treated
with 10 nM FVIIa for 1 h prior to stimulation with 1 μg/ml ephrin-A1 for 10, 30 and 60 min. Cells were fixed and stained with FITC-conjugated
phalloidin and micrographs generated by epifluorescence microscopy. Ephrin-A1 treatment induced cell rounding and retraction fiber formation,
which was potentiated by FVIIa to 49.7 ± 4.4 % vs 29.3 ± 4.1 % at 10 min (p =0.009), 30.9 ± 8.9 % vs 16.2 ± 1.6 % at 30 min (p= 0.08) and 25.4 ± 7.5 % vs
13.3 ± 2.9 % at 60 min (p= 0.010). FVIIa alone did not increase cell rounding and retraction fiber formation compared to untreated cells (7.3 ± 4.5 % vs 5.2
± 2 %, p= 0.49). N= 3, results are expressed as means ± SD of the percentage of rounded cells with retraction fibers. Representative images are shown
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As demonstrated by others [17, 24], stimulation with
ephrin-A1 caused a transient increase in cell rounding
which peaked at 10 min. Phalloidin staining revealed an
accumulation of actin fibers at cell borders and an in-
crease in retraction fibers, which were formed as cells
rounded up and retracted their protrusions [25]. To in-
vestigate a role for TF/FVIIa in this process cells were
pre-incubated with 10 nM FVIIa, and then simulated
with ephrin-A1 followed by phalloidin staining. In this
context FVIIa alone caused no detectable changes in cell
morphology. However, upon FVIIa pretreatment the cel-
lular response to ephrin-A1 was greatly enhanced. The
fraction of rounded cells with retraction fibers upon
ephrin-A1 stimulation was increased by FVIIa preincu-
bation at all time points, demonstrating a potentiation of
ligand-dependent EphA2 activation (Fig. 3b).
As FVIIa cleaved EphA2 independently of PAR2 we
tested the requirement of PAR2 in this context. Block-
ing experiments with an anti-PAR2 antibody and the
anti-TF 10H10 antibody which selectively prevents
PAR2 activation did not interfere with the synergistic
effects of FVIIa and ephrin-A1 on cell rounding, dem-
onstrating that this occurs independently of PAR2
(Fig. 4). Experiments with active site-inhibited FVII
Fig. 4 Potentiation of ephrin-A1-induced cell rounding and retraction fiber formation by FVIIa is independent of PAR2. MDA-MB-231 cells were pretreated
with 50 μg/ml anti-TF antibody 10H10 or 100 μg/ml PAR2-blocking antibody for 30 min, stimulated with 10 nM FVIIa for 1 h and then 1 μg/ml ephrin-A1
for 10 min. Alternatively, 10 nM active-site inhibited FVII (FFR-FVII) was added instead of FVIIa. Potentiation of cell rounding and retraction fiber formation
was not prevented by the anti TF 10H10 antibody (43.4 ± 4.2 % vs 16.6 ± 9.2 %, p= 0.01) or a PAR2-blocking antibody (31.4 ± 9.9 % vs 8.1 ± 4.6 %, p= 0.02),
FFR-FVII did not increase cell rounding and retraction fiber formation together with ephrin-A1 (14.3 ± 5.7 % vs 14.4 ± 1.2 %, p= 0.99). N= 3, results are
expressed as means ± SD of the percentage of rounded cells with retraction fibers. Representative images are shown
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(FFR-FVII) confirmed the requirement for the proteo-
lytical activity of FVIIa to synergistically enhance the
ephrin-A1 response (Fig. 4).
Cell rounding induced by FVIIa and ephrin-A1 is
dependent on a RhoA/ROCK pathway
We next sought to gain insight into the downstream
signaling mechanisms. A serine residue in the cytoplas-
mic domain of EphA2, serine 897 (S897), was recently
discovered as an important phosphorylation site medi-
ating cell motility downstream of PI3K/Akt signaling
[9]. Western blots of FVIIa-treated MDA-MB-231 cells
revealed a strong increase in S897 phosphorylation by
10 nM FVIIa, which was completely abolished by the
PI3 kinase inhibitor LY294002 (Fig. 5a). In contrast,
EphA2 cleavage was not affected by PI3 kinase inhib-
ition (Fig. 5a), in agreement with a direct cleavage by
FVIIa and demonstrating that TF/FVIIa targets EphA2
by two independent mechanisms. We tested the PI3K-
dependence in the cell rounding assay, but the PI3K
inhibitor LY294002 did not affect the synergistic effect
of FVIIa and ephrin-A1, ruling out a mechanism
dependent on this pathway (Fig. 5b).
Instead, ligand-dependent EphA2 activity targeting the
cytoskeleton has been reported to be dependent on
RhoA signaling [26]. Preincubation of cells with 10 μM
Y-27632, an inhibitor of the RhoA signaling effector
ROCK, abolished cell rounding by ephrin-A1 and FVIIa
(Fig. 5b). We confirmed this result by knocking down
RhoA with siRNA. RhoA-depleted cells were almost
completely unresponsive to ephrin-A1 with regards to
cytoskeletal rearrangements and maintained a spread
morphology both when treated with ephrin-A1 alone or
in combination with FVIIa, showing a mechanism
dependent on a RhoA/ROCK pathway downstream of
EphA2 (Fig. 5c).
These results demonstrated a synergistic effect of
ephrin-A1 and FVIIa in EphA2 activation independent of
PAR2-signaling and PI3K-dependent serine phosphoryl-
ation of EphA2, and EphA2 was cleaved by TF/FVIIa in a
PAR2- and PI3K-independent manner. Yet, the cleavage
by TF/FVIIa occurs in the EphA2 LBD. However, the N-
terminal fragment remains attached to the truncated
EphA2 species by a disulfide bond [16], raising the possi-
bility that it might still be responsive to ephrin-A1. Being
an RTK, EphA2 has intrinsic tyrosine kinase activity that
is activated by ligand-binding and we examined EphA2 ac-
tivation by FVIIa and ephrin-A1 by using an antibody to-
wards phosphorylated tyrosine 588 (Y588) in the EphA2
cytoplasmic domain. Western blots showed low tyrosine
phosphorylation in the basal state, which was slightly but
consistently increased by FVIIa as seen on high-exposure
Western blots (Fig. 6a). Ephrin-A1 treatment resulted in a
rapid and strong tyrosine phosphorylation of full-length
EphA2 that, however, was not further increased by
FVIIa pretreatment. The cleaved EphA2 species was
also rapidly tyrosine phosphorylated by ephrin-A1,
which was detected after 1 h or 6 h pre-treatment with
FVIIa (Fig. 6b-c). Cleaved EphA2 also appeared to
undergo rapid ligand-induced downregulation, as we
consistently found a time-dependent reduction of the
band corresponding to cleaved EphA2 after ephrin-A1
stimulation, as seen on the 10 min ephrin-A1 time
point in Fig. 6b. Taken together, these results indicate
that cleaved EphA2 is activated in response to stimula-
tion with ephrin-A1.
TF and EphA2 are co-expressed in advanced stage
colorectal cancers and appear close to necrotic and
invasive areas
TF expression has previously been detected in many
solid tumors, including colorectal cancers [27], and has
been linked to tumor progression on an experimental
level using animal models and in vitro cell culture sys-
tems [13]. To explore if a role for TF-EphA2 cross-talk
in this context is plausible we stained a cohort of colo-
rectal cancer specimens for TF and EphA2 by IHC and
scored their expression levels in tumor cells. IHC stain-
ings on normal colorectal mucosa showed that epithelial
cells in the large intestine were mostly negative for TF,
while strong staining was seen in the epithelial lining.
EphA2 expression was present in the most apical parts of
the colorectal epithelium while basal portions of the
glands were negative, in agreement with previous ob-
servations [28] and demonstrating antibody specificity
(Additional file 1). EphA2 expression then reappeared in
cancer specimens, along with increased positivity for TF.
TF expression was detected in 28 % of primary cancers
and 29 % of lymph gland or distant metastases, and
EphA2 in 59 % of cases in both groups (Table 1). Interest-
ingly, annotation scores for TF and EphA2 expression
correlated (Spearman Rho 0.48, p < 0.001), with 87 % of
TF positive primary tumors and 100 % of TF positive me-
tastases also being positive for EphA2, demonstrating that
TF and EphA2 are co-expressed in colorectal carcinomas.
We also investigated if combined expression of TF and
EphA2 was related to tumor characteristics in primary tu-
mors. Co-expression of TF and EphA2, compared to nega-
tivity for either of the two proteins, was significantly
associated with poorly differentiated histology (high grade
tumors), as six out of 13 (46 %) cases in this group were
double positive compared to only seven out of 39 (18 %)
cases with intermediate/high differentiation (low to inter-
mediate grade) (p = 0.042) (Table 2). Notably, staining of
serial sections revealed that TF and EphA2 positivity ap-
peared to be concentrated to clusters of tumor cells close
to necrotic areas or small clusters of budding tumor cells
invading through the stroma (Fig. 7a–b).
Eriksson et al. BMC Cancer  (2016) 16:341 Page 8 of 14
Fig. 5 Cell rounding and retraction fiber formation in response to FVIIa and ephrin-A1 is dependent on a RhoA/ROCK pathway. a MDA-MB-231
cells were pre-incubated with either DMSO or 25 or 50 μM PI3K inhibitor LY294002 before 10 nM FVIIa was added for 1 h. Samples were analyzed
by Western blot. S897-phosphorylation was increased to 163.1 ± 30.2 % of control in DMSO-treated cells (p = 0.006), whereas 25 μM or 50 μM
LY294002 abolished induction by FVIIa to 96.4 ± 8.6 % vs 77.1 ± 11.7 % (p = 0.08) or 89.9 ± 6.7 % vs 91.7 ± 8.1 % (p = 0.78), respectively. Values are
expressed as % of control. N = 3–4, results are presented as means ± SD. b MDA-MB-231 cells were pretreated with 10 μM ROCK-inhibitor Y-27632 or
25 μM PI3K inhibitor LY294002 for 30 min and then stimulated as in Fig. 4. Y-27632 pre-treatment abolished the effects of ephrin-A1 as well as the
potentiation by FVIIa (4.8 ± 1.3 % vs 4.6 ± 4.1 %, p = 0.93), while LY294002 had no effect (32.5 ± 7.3 % vs 14.6 ± 4.9 %, p = 0.007). N = 3–4, results are
expressed as means ± SD of the percentage of rounded cells with retraction fibers. c RhoA expression was silenced by siRNA in MDA-MB-231 cells, and
knock-down was verified by Western blot. In Scr-transfected cells FVIIa potentiated ephrin-A1 induced cell rounding (35.87 ± 14.80 vs 10.49 ± 4.29 %,
p = 0.046), whereas RhoA knock-down cells were unresponsive to ephrin-A1 and FVIIa (3.30 ± 2.50 % vs 0.92 ± 0.88 %, p = 0.19). N = 3, results are
expressed as means ± SD of the percentage of rounded cells with retraction fibers
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Discussion
We report herein on a close cross-talk between TF and
the tyrosine kinase receptor EphA2 and present evidence
of a role for the TF/FVIIa complex as a co-receptor and
signaling partner of EphA2 with possible implications in
human cancer. We observed that TF and EphA2 co-
localized in MDA-MB-231 breast cancer cells with high
endogenous TF expression, and in U251 glioblastoma
cells with forced overexpression of TF. EphA2 and TF
appeared to cluster at cell-cell contacts and subcellular
compartments with an accumulation of dynamic actin
cytoskeleton, in agreement with literature documenting
Fig. 6 EphA2 is tyrosine phosphorylated by FVIIa and ephrin-A1. a MDA-MB-231 cells were treated with 10 nM FVIIa and samples were analyzed by
Western blot for EphA2 phosphorylation on tyrosine 588 (Y588) and total EphA2 protein. FVIIa increased the phosphotyrosine signal to 110.0 ± 1.02 %
(p < 0.001) after 30 min and 129.2 ± 9.82 % (p = 0.0067) after 60 min. N = 3, results are presented as means ± SD. b MDA-MB-231 cells were pretreated
with 10 nM FVIIa for 1 h and then stimulated with 1 μg/ml ephrin-A1-Fc for 5 or 10 min. c MDA-MB-231 cells were pretreated with 10 nM FVIIa for 6 h
and then stimulated with 1 μg/ml ephrin-A1-Fc for 5 min. Samples were analyzed by Western blot as in (a). N = 2–3, representative gels are shown










All cases 54 15 39 n/a
EphA2
positive 32 (59) 13 (87) 19 (49) 0.011
negative 22 (41) 2 (13) 20 (51)
Metastases
All cases 17 5 12 n/a
EphA2
positive 10 (59) 5 (100) 5 (42) 0.026
negative 7 (41) 0 (0) 7 (58)
P-values in bold indicate statistically significant results
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an important role for EphA2 in regulating cytoskeletal
dynamics [29, 30]. Importantly, we found that FVIIa po-
tentiated the cellular response to ephrin-A1 as measured
by increased cell rounding and retraction fiber formation
upon stimulation, demonstrating that FVIIa and ephrin-
A1 act synergistically to enhance ligand-dependent
EphA2 signaling. By antibody blocking experiments, we
show that this is an event uncoupled from PAR2-
activation, in line with biochemical data demonstrating
direct cleavage of EphA2 by TF/FVIIa, and supporting a
role of the TF/FVIIa complex acting as a co-receptor in
EphA2 signaling.
EphA2 is cleaved by FVIIa after a conserved arginine
residue in the J-K loop of the LBD, and we previously
showed that the cleaved fragment remains associated to
the truncated EphA2 by a conserved disulfide bond
(Cys70-Cys188), and the LBD is also stabilized by an
additional disulfide (Cys105-Cys115). Since the Cys70-
Cys188 disulfide will prevent dissociation of the N-
terminal fragment we predict that the structure of the
EphA2 LBD is largely retained after cleavage, with the
cleavage leading to a local conformational change in the
J-K loop. We hypothesize that cleavage by TF/FVIIa
might, by a yet unidentified exact mechanism, enhance
EphA2 activation by its ligand. As it was tyrosine phos-
phorylated and rapidly underwent ligand-induced degrad-
ation, our data indicate that the cleaved fragment indeed
contributes to ephrin-A1-dependent signaling and that
the cleavage does not results in a ligand-unresponsive
form of EphA2. Of note, as the synergism between FVIIa
and ephrin-A1 was PAR2-independent in line with the
cleavage mechanism, it appears not to be an unrelated
event resulting from PAR2 activation by TF/FVIIa.
EphA2 tyrosine phosphorylation was very low in un-
stimulated cells, which was expected since MDA-MB-
231 cells are reported to express very low amounts of
the ephrin-A1 ligand [8]. We observed a slight increase
of phosphorylation at the Y588 site by FVIIa, but since
this effect was negligible compared to the response in-
duced by ephrin-A1 the relevance of this observation
with regards to synergism between FVIIa and ephrin-A1
is not clear at the moment. Of note, we previously ana-
lyzed this cell line using antibody arrays [16], where
FVIIa decreased the phosphotyrosine signal for EphA2
and as we noted, since those experiments were run with
native samples a decrease in signal can equally well cor-
respond to masking of the phosphotyrosine epitope by
proteins recruited to the activated receptor [31].
Fig. 7 EphA2 and TF are co-expressed in a colorectal cancer. Representative images of immunohistochemistry stainings for TF and EphA2. Brown color
represents positive staining. a Serial sections from specimen with high expression of TF (left panel) and EphA2 (right panel). Original magnification 20×.
b Serial sections from specimen with scattered positivity for TF (left panel) and EphA2 (right panel) localized to necrotic areas and budding tumor cells.
Original magnification 40 ×
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Even though a large number of studies have confirmed
an important role of EphA2 in human cancers, there are
controversies regarding the contributions of ligand
dependent and ligand independent signaling. Ephrin-A1
ligation of EphA2 and subsequent receptor activation
has been proposed to be tumor suppressive, although
other studies point to an important role for kinase
dependent EphA2 activity in cancer development. Cell
rounding and retraction is a recognized event in Eph-
ephrin signaling, and requires RhoA activation [6, 7], in
accordance with our results. Interestingly, recent work
suggest that EphA2-ephrin-A1 signaling may support
cell migration and invasion in prostate cancer [5] and
melanoma cells [6] in this manner. Here, RhoA-
mediated mesenchymal-to-amoeboid transition has been
implicated, indicating a qualitative shift in cell migration
characterized by cell rounding, single cell invasion and a
squeezing movement style, leading to tissue invasion
and tumor dissemination [32, 33]. Also, other studies
demonstrated that repulsive EphA2-RhoA signaling
among cancer cells may serve to allow tumor cells to
disperse from the main tumor mass [26]. Importantly,
contact inhibition of locomotion which may occur as a
consequence of repulsive interactions between Eph and
ephrin expressing cells does not need to lead to a
complete inhibition of motility but rather a change in
direction, in certain contexts contributing to a shift from
collective to single cell cancer invasion [34]. In this con-
text, our results demonstrating a synergism of FVIIa and
ephrin-A1 in EphA2 activation lead us to hypothesize
that TF/FVIIa may serve to increase EphA2-mediated
cell dispersion upon contact with ephrin-A1 expressing
cells, and that FVIIa may facilitate ephrin-A1 induced
mesenchymal-to-amoeboid transition in this context.
EphA2 signaling is characterized by a high level of
complexity and several seemingly independent activation
mechanisms, as demonstrated by the present study
where FVIIa caused both a direct cleavage and S897
phosphorylation of EphA2. While cleavage was insensi-
tive to PI3 kinase inhibition, S897 phosphorylation was
completely abolished in agreement with the notion that
this is a common event downstream of activation of PI3
kinase. Cell rounding and retraction fiber formation was
not affected by PI3K inhibition, showing a dissociation
between EphA2-pS897 signaling and ligand-dependent
EphA2 activation as has been proposed elsewhere [9].
The role and function of FVIIa-induced EphA2 S897-
phosphorylation was not elucidated in this study, and its
role as an effector downstream of FVIIa-induced PI3K
activation will be an important issue for further studies.
In support of the relevance of TF/FVIIa-EphA2 cross-
talk we present descriptive data that TF and EphA2 were
co-expressed to a high extent in a human cancer mate-
rial, and TF positivity was with a few exceptions only
found in EphA2 expressing tumors. TF and EphA2 have
separately been reported to be expressed in various
cancers, but our study is the first to demonstrate co-
expression in the same tumor specimens. In contrast to
our experimental work that was performed in breast
cancer and glioblastoma cell lines, we used another
cancer type, colorectal cancer, to demonstrate the associ-
ation between TF and EphA2 in human tumor tissue.
Although these are distinct cancer types, both TF and
EphA2 expression appears to foremost be a feature of
advanced cancers, and TF expression is regulated by
common oncogenic mutations [35]. Indeed, EphA2 has
been linked to colorectal cancer development as targeted
EphA2 gene disruption was found to reduce intestinal
tumorigenesis in the APC/Min +mouse model [36]. We
found that co-expressing tumors were enriched among
high-grade cases, supporting the view that these results
may be a feature of poorly differentiated human cancers
rather than a tissue specific event in colorectal neo-
plasms. TF expression was, for both primary cancers
and metastases, found in a minority of cases, and our re-
sults indicate that TF and EphA2 co-expression is an
event that occurs in a subset of colorectal cancers that
are characterized by low differentiation. As a large num-
ber of cases were TF negative, this might be a mecha-
nism that contributes to tumorigenesis in a subset of
tumors, whereas other oncogenic pathways drive more
differentiated cancers. Here, future studies on larger
clinical materials will have to provide answers on the
possible impact on patient survival and outcome.
We previously noted that higher concentrations of
FVIIa were needed for cleavage of EphA2 compared to
cleavage of another Eph receptor, EphB2. In the present
study, overexpression of TF was required to achieve
EphA2 cleavage by FVIIa in U251 cells and it thus ap-
pears that very high levels of TF, such as may be found
in transformed cells are necessary for this to occur.
However, high levels of both TF and EphA2 are recog-
nized events in malignant cells, and we used a colorectal
cancer material to show that co-expression of TF and
EphA2 indeed occurs in vivo. In addition, cleavage of
cellular subpopulations with EphA2 co-localizing with
TF may also play important biological roles even though
these are events that are below the detection limit of
Western blot assays.
Conclusion
In summary, we show with a proximity ligation assay and
immunofluorescence that TF and EphA2 co-localize in
cancer cell lines and that TF/FVIIa cleaves EphA2 in cells
with high TF expression in a PAR2-independent manner.
FVIIa stimulation increased ephrinA1-induced cell roun-
ding mediated by a RhoA/ROCK pathway and thus po-
tentiated ephrin-A1-EphA2 cytoskeletal rearrangements,
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with a potential role in mesenchymal-to-amoeboid
transition mediated by the EphA2-ephrin-A1 axis. We
also present initial evidence that EphA2 and TF are
co-expressed in vivo in poorly differentiated colorectal
tumors, thus warranting further studies on their co-
operative role in human cancers.
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